** Hikma Pharmaceuticals, Shire, Qiagen, BB Biotech fall 3-5 pct
** Track weakness overnight in US healthcare,dragged down by >5% drop in Mylan as political pressuremounted on company after price increases for its EpiPen allergytreatment
** Democratic presidential candidate Hillary Clinton calledfor lower price on EpiPen (up >400% in the past decade)
** Hikma hits 2-mth low; extends losses from Wednesday whenit posted 14 pct drop in H1 core operating profit
** European healthcare subsector currently -2.2 pct,worst performer of Pan European Stoxx
** Hikma is the worst performer on Stoxx 600,followed by Shire